| Autor: |
Kyohei Ishida, Go Hasegawa, Toshinori Takada, Akira Ogose, Gen Kawaguchi, Yohei Ikeda, Hiroki Nishiyama, Noboru Hara, Tsutomu Nishiyama |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Case Reports in Urology, Vol 2024 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2090-6978 |
| DOI: |
10.1155/2024/6648459 |
| Popis: |
We encountered a case of metastatic renal cell carcinoma in which the serum level of KL-6, a therapeutic marker, was exceptionally high and fluctuated with the progression of treatment. A 74-year-old man was diagnosed with right renal cystic cancer and multiple metastases in October 2022. The KL-6 level was 27490 U/mL. He started treatment with lenvatinib and pembrolizumab. KL-6 decreased to 3885 U/mg in February 2023. The patient’s proteinuria worsened, leading to the discontinuation of lenvatinib. KL-6 increased to 25950 U/mL in April. He discontinued pembrolizumab and started taking cabozantinib. In September, drug-induced bilateral inflammatory pneumonitis developed. He discontinued cabozantinb and began taking axitinib. KL-6 decreased; however, he suffered from severe diarrhea and subsequent renal insufficiency. He discontinued axitinib in November. KL-6 increased to 29640 U/mL in December. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text